Bruker Corporation is launching iNTApharma, a label-free characterization platform featuring single-particle sensitivity to quantitatively analyze nanoscale bioparticles. Evaluating these particles in native aqueous media, the platform can provide size and concentration measurements in just minutes.

This, according to Bruker, supports research, therapy development, and quality control workflows requiring direct assessment without labeling or chemical modifications.

Importance of Nanoscale Characterization

Bruker said native-state nanoparticle tracking analysis (NTA)—from which iNTApharma gets its name—is increasingly required in biopharma quality control. Quantitative characterization in native conditions is relevant to extracellular vesicle research, adenovirus development, lentiviral vector analysis, and lipid nanoparticle formulation.

According to Bruker, both messenger RNA (mRNA) and cell and gene therapy development are rapidly expanding. Therefore, high-precision characterization demand is increasing.

Jürgen Srega, President of the Bruker CALID Group, illustrated this market shift.

“Native‑state, quantitative analysis of lipid nanoparticles, lentiviral vectors, and vesicle‑scale bioparticles is a growing need,” Srega said. “With iNTApharma, we are introducing a fundamentally new tool that enables precise nanoparticle and bioparticle characterization.”

Specifically, iNTApharma works with bioparticles ranging from 50 to 300 nanometers. These conditions align with lipid nanoparticles, lentiviral vectors, adenoviruses, and extracellular vesicles.

Development of Bruker Platform

The platform builds on approaches developed at the Max-Planck-Institute for the Science of Light (MPL) in Erlangen, Germany. MPL Director Vahid Sandoghdar spotlighted some advantages.

“[iNTApharma uses] iSCAT [interferometric scattering] microscopy, which has been used in a wide range of quantitative label‑free investigations,” Sandoghdar said. “iNTApharma makes these capabilities broadly available and provides researchers with a tool that can deepen our understanding of nanoscale bioparticles.”

Throughout the rest of the first half of 2026, Bruker will place initial iNTApharma systems with early-access partners. Doing this will validate workflows under real-world conditions as a result.

As of now, broader commercial availability will come in the second half of 2026.